What did the FDA approval of Trutakna mean for IgA nephropathy treatment?

In July 2026, the FDA granted accelerated approval to Vera Therapeutics’ Trutakna (atacicept‑vymj) for adults with IgA nephropathy at risk of progression. The weekly injection, which targets BAFF and APRIL, showed a 46% reduction in proteinuria versus placebo. Ongoing trials will determine if it also slows long‑term kidney decline.